Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bone marrow transplantation: does it stop MS progression?

Mark S Freedman1

  • 1University of Ottawa, The Ottawa Hospital, General Campus, Ottawa, Ontario, Canada. mfreedman@ottawahospital.on.ca

Journal of the Neurological Sciences
|June 15, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Patient reported outcomes in NMOSD reflect a high disease burden and do not correlate with the EDSS.

Multiple sclerosis and related disorders·2026
Same author

Serum metabolic profile at clinical onset as predictor of multiple sclerosis activity and progression after 5 years.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Long-term safety and efficacy of ponesimod in participants with relapsing multiple sclerosis: results from the phase 3 OPTIMUM 5-year long term extension study.

Journal of neurology·2026
Same author

Best practice recommendations for laboratory analysis and reporting of cerebrospinal fluid oligoclonal banding and associated tests for multiple sclerosis (MS): a consensus report from the harmonized CSF analysis for MS investigation (hCAMI) subcommittee of the Canadian society of clinical chemists (CSCC).

Clinical biochemistry·2026
Same author

Demographic and Clinical Characteristics of Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder in Canadian Adults.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques·2026
Same author

Lipoic Acid for Treatment of Progressive Multiple Sclerosis: A Phase 2 Randomized Clinical Trial.

Neurology·2025
Same journal

Distinguishing drug-target effects from natural lipid variation and incorporating imaging outcomes in Mendelian randomisation studies of multiple sclerosis.

Journal of the neurological sciences·2026
Same journal

Long-term social cognitive impairment after ischemic stroke: Frequency and association with lesion volume and location in an exploratory pilot study.

Journal of the neurological sciences·2026
Same journal

Subjective cognitive decline among U.S. Cancer survivors, 2017-2024: Prevalence, cancer-specific patterns, and associated factors.

Journal of the neurological sciences·2026
Same journal

Comment on "Comparative impact of mental and cardiovascular comorbidities on adverse outcomes in people with MS".

Journal of the neurological sciences·2026
Same journal

Comment on "Efficacy and safety of conventional immunosuppressant therapies in elderly patients with Neuromyelitis optica spectrum disorder: A target trial emulation study".

Journal of the neurological sciences·2026
Same journal

Increasing incidence of varicella-zoster virus meningitis in Japan, 2011-2022.

Journal of the neurological sciences·2026
See all related articles

Hematopoietic stem cell transplantation may induce long-lasting remission in multiple sclerosis (MS) by replacing the immune system. This approach targets MS as an acquired autoimmune condition, not solely genetic.

Area of Science:

  • Neuroimmunology
  • Autoimmune Diseases
  • Regenerative Medicine

Background:

  • Multiple Sclerosis (MS) is theorized to be an acquired autoimmune disease.
  • Current treatments aim to manage symptoms but not provide a cure.
  • Genetic factors alone do not fully explain MS etiology.

Purpose of the Study:

  • To explore the potential of autologous hematopoietic stem cell transplantation (aHSCT) for long-lasting MS remission.
  • To present the rationale and methodology for using aHSCT in MS.
  • To review existing study results and preliminary data from ongoing research.

Main Methods:

  • Complete ablation of the patient's immune system.
  • Infusion of autologously-obtained hematopoietic stem cells.

Related Experiment Videos

  • Establishing a new, non-disease-causing immune system de novo.

    • Main Results:

    • Presentation of results from several small-scale studies on aHSCT for MS.
    • Inclusion of preliminary data from a Canadian research effort.
    • Evidence suggesting potential for long-lasting disease remission.

    Conclusions:

    • aHSCT offers a promising therapeutic strategy for MS based on its autoimmune theory.
    • Patient selection is crucial for successful outcomes with this approach.
    • Further research and ongoing trials are essential to validate efficacy and long-term safety.